Sol J. Barer
Known title: DirectorCIK: 0001247015
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▲ Buy | Option Exercise | 21,739 | — | 6/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 17,158 | — | 6/6/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 37,598 | — | 6/15/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 28,162 | — | 8/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 25,791 | — | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.